Affiliations: Depts. of Dept. of Nuclear Medicine, Mem. Sloan-Kettering Cancer Center, New York, NY, United States
Department of Pediatrics, Mem. Sloan-Kettering Cancer Center, New York, NY, United States
AnorMed Inc., Langley, BC, Canada
References: Abrams, M.J., Juweid, M., Tenkate, C.I., Schwartz, D.A., Hauser, M.M., Gaul, F.E., Fuccello, A.J., Fischman, A.J., Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats (1990) J. Nucl. Med., 31, pp. 2022-202
Arbit, E., Yeh, S.J., Cheung, N.K., Larson, S.M., Quantitative Immunoimaging of gliomas in humans with anti-ganglioside monoclonal antibodies [abstract] (1991) J. Neurosurg., 76, p. 399
Barrow, S.A., Graham, W., Jyawook, S., Dragotakes, S.C., Solomon, H.F., Babich, J.W., Rubin, R.H., Fischman, A.J., Localization of indium-111-immunoglobulin G, technetium-99m-immunoglobulin G and indium-111-labeled with blood cells at sites of acute bacterial infection in rabbits (1993) J. Nucl. Med., 34, pp. 1975-1979
Blauenstein, P., Locher, J.T., Seybold, K., Koprivova, H., Janoki, G.A., Mache, H.R., Hasler, P., Schubiger, P.A., Experience with the iodine-123 and technetium-99m labelled anti-granulocyte antibody Mab47: A comparison of labelling methods (1995) Eur. J. Nucl. Med., 22, pp. 690-698
Boonkitticharoen, V., James, H., Cheung, N.K.V., Larson, S.M., Finn, R.D., Optimizing the recovery of chemically reduced monoclonal antibody for site specific technetium-99m radiolabeling (1993) Biotechniques, 14, pp. 706-707
Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Anal. Biochem., 72, pp. 248-274
Brummendorf, T.H., Kaul, S., Schuhmacher, J., Baum, R.P., Matys, R., Klivenyi, G., Adams, S., Bastert, G., Immunoscintigraphy of human mammary carcinoma xenografts using monoclonal antibodies 12H12 and BM-2 labeled with 99mTc and radioiodine (1994) Cancer Res, 54, pp. 4162-4168
Callahan, R.J., Barrow, S.A., Abrams, M.J., Rubin, R.H., Fischman, A.J., Biodistribution and dosimetry of technetium-99m-hydrazino nicotinamide IgG: Comparison with indium-111-DTPA-IgG (1996) J. Nucl. Med., 37, pp. 843-846
Chang, H.R., Cordon-Cardo, C., Houghton, A.N., Cheung, N.K.V., Casper, E.S., Brennan, M.F., Expression of disialogangliosides GD2 and GD3 by human soft tissue sarcomas (1992) Cancer, 70, pp. 633-638
Cheung, N.K., Landmeier, B., Neely, J., Nelson, D., Abramowsky, C., Ellery, S., Adams, R., Miraldi, F.D., Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice (1986) J. Natl. Cancer Inst., 77, pp. 739-745
Cheung, N.K., Neely, J.E., Landmeier, B., Nelson, D., Miraldi, F., Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma (1987) J. Nucl. Med., 28, pp. 1577-1583
Cheung, N.K., Pentlow, K., Graham, M.C., Yeh, S.D.J., Finn, R.D., Larson, S.M., Radioimmunotherapy of human neuroblastoma using monoclonal antibody 3F8 (1992) In: Fifth International Radiopharmaceutical Dosimetry Symposium, pp. 95-112. , Oak Ridge Associated Universities, Oak Ridge, TN
Cheung, N.K., Saarinen, U.M., Neely, J.E., Landmeier, B., Donovan, D., Coccia, P.F., Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells (1985) Cancer Res, 45, pp. 2642-2649
Childs, R.L., Hnatowich, D.J., Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m (1985) J. Nucl. Med., 26, pp. 293-299
Desphande, S.V., Denardo, S.J., Meares, C.F., Copper-67-labeled monoclonal antibody LYM-1 a potential radiopharmaceutical (1988) J. Nucl. Med., 29, pp. 217-225
Eckelman, W.C., Paik, C.H., Steigman, J., Three approaches to radiolabeling with 99mTc (1989) Nucl. Med. Biol., 16, pp. 171-176
Fraker, P.J., Speck, J.C., Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril (1978) Biochem. Biophys. Res. Commun., 80, pp. 849-857
Fritzberg, A.R., Abrams, P.G., Beaumier, P.L., Kasina, S., Morgan, A.C., Rao, T.N., Reno, J.M., Vanderheyden, J.L., Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent (1988) Proc. Natl. Acad. Sci. USA, 85, pp. 4025-4029
Furukawa, K., Akagi, T., Nagata, Y., Yamada, Y., Shimotohno, K., Cheung, N.K.V., Shiku, H., Furukawa, K., GD2 ganglioside on human T lymphotropic virus type I-infected T cells: Possible activation of beta-1,4N-acetylgalactosaminyl-transferase gene by p40-tax (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 1972-1976
Grant, S.C., Kostakoglu, L., Kris, M.G., Yeh, S., Larson, S.M., Finn, R.D., Oettgen, H.F., Cheung, N.K.V., Radioimmunodetection of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial (1996) Eur. J. Nucl. Med., 23, pp. 145-149
Heiner, J., Miraldi, F.D., Kallick, S., Makley, J., Smith-Mensah, W.H., Neely, J., Cheung, N.K.V., In vivo targeting of GD2 specific monoclonal antibody in human osteogenic sarcoma xenografts (1987) Cancer Res, 47, pp. 5377-5381
Hiltunen, J.V., Search for new and improved radiolabeling methods for monoclonal antibodies (1993) Acta Oncol, 32, pp. 831-839
Hnatowich, D.J., Mardirossian, G., Rusckowski, M., Fogarasi, M., Virzi, F., Winnard P., Jr., Directly and indirectly technetium-99m-labeled antibodies - A comparison of in vitro and animal in vivo properties (1993) J. Nucl. Med., 34, pp. 109-119
Kozak, R.W., Raubitschek, A., Mirzadeh, S., Brechbiel, M.W., Junghaus, R., Gansow, O.A., Waldman, T.A., Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity (1989) Cancer Res, 49, pp. 2639-2644
Larsen, S.K., Solomon, H.F., Caldwell, G., Abrams, M.J., 99mTc Tricine: A useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates (1995) Bioconjug. Chem., 6, pp. 635-638
Larson, S.M., Sgouros, G., Cheung, N.K., Antibodies in cancer therapy: Radioisotope conjugates (1995) Biologic Therapy of Cancer 2nd Edn, pp. 534-552. , V.T. DeVita, S. Hellman, & S.A. Rosenberg. Philadelphia: J.B. Lippincott
Mather, S.J., Ellison, D., Reduction-mediated technetium-99m labeling of monoclonal antibodies (1990) J. Nucl. Med., 31, pp. 692-697
Miraldi, F.D., Nelson, A.D., Kraly, C., Ellery, S., Landmeier, B., Coccia, P.F., Strandjord, S.E., Cheung, N.K.V., Diagnostic imaging of human neuroblastoma with radiolabeled antibody (1986) Radiology, 161, pp. 413-418
Moffat, R., Pinsky, C.M., Hammershaimb, L., Petrelli, N.J., Patt, Y.Z., Whaley, F.S., Goldenberg, D.M., Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group (1996) J. Clin. Oncol., 14, pp. 2295-2305
Ram, S., Buchsbaum, D.J., A peptide-based bifunctional chelating agent for Tc-99m and Re-186 labeling of monoclonal antibodies (1994) Cancer, 73, pp. 769-773
Rhodes, B.A., Zamora, P.O., Newell, K.D., Valdez, E.F., Technetium-99m labeling of murine monoclonal antibody fragments (1994) J. Nucl. Med., 27, pp. 685-693
Schwartz, A., Steinstrasser, A., A novel approach to Tc-99m-labeled monoclonal antibodies [abstract] (1987) J. Nucl. Med., 28, p. 721
Schwartz, D.A., Abrams, M.J., Hauser, M.M., Gal, F.E., Larsen, S.K., Rauh, D., Zubieta, J.A., Preparation of hydrazino-modified proteins and their use for the synthesis of 99mTc-protein conjugates (1991) Bioconjug. Chem., 2, pp. 333-336
Thakur, M.L., Defulvio, J.D., Technetium-99m-labeled monoclonal antibodies for immunoscintigraphy (1991) J. Immunol. Methods, 137, pp. 217-223
Thakur, M.L., Kolan, H.R., Rifat, S., Li, J., Rux, A., John, E., Halmos, G., Schally, A.V., Valpreotide labeled with Tc-99m for imaging tumors: Preparation and preliminary evaluation (1996) Int. J. Oncol., 9, pp. 445-451
Weinstein, J.N., Eger, R.R., Covell, D.G., Larson, S.M., Keenam, A.M., The pharmacology of monoclonal antibodies (1987) Ann. NY Acad. Sci., 507, pp. 199-210
Yeh, S.D., Larson, S.M., Burch, L., Kushner, B.H., Laquaglia, M., Finn, R., Cheung, N.K.V., Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-Metaiodobenzylguanidine (MIBG) and standard diagnostic modalities (1991) J. Nucl. Med., 32, pp. 769-776
Zhang, S., Filippa, D.A., Zhang, H.S., Zelenetz, A., Scheinberg, D., Livingston, P., Expression of GM2 and GD2 in B cell lymphomas: Targets for immune attack [abstract] (1997) Proc. Am. Assoc. Cancer Res., 38, p. 404
99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors
3F8 is a murine IgG3 monoclonal antibody (MAb) selective for the ganglioside G(D2). Previous studies using 131I-3F8 have shown great potential in the imaging of neuroectodermal tumors and the therapy of human neuroblastoma. 131I is commonly used in radioimmunodiagnosis, but its relatively long half-life (8 days) and its high energy γ-emission (364 KeV) are suboptimal for imaging purposes when compared with 99mTc (6 h and 140 KeV, respectively). To label 3F8 with 99mTc, the antibody was first coupled with a heterobifunctional linker, succinimidyl-6-hydrazinonicotinate hydrochloride (SHNH), obtaining a hydrazinonicotinamide-antibody conjugate. Using 99mTc-Tricine as the precursor complex, 3F8-SHNH was coupled efficiently to 99mTc, resulting in >90% radiometal incorporation, with a specific activity >10 mCi/mg and retaining full immunoreactivity. Immunoscintigraphy at 6, 22, and 46 h after intravenous injection of 1 mCi of 99mTc-3F8 showed selective neuroblastoma localization in xenografted nude mice, comparable to that obtained with the injection of 100 μCi of 131I-3F8. Biodistribution studies of 131I-3F8 and 99mTc-3F8 in mice demonstrated comparable %ID/g uptake in tumor (with a T/B ratio: ~2.5 at 24 h and ~3.5 at 48 h) and normal organs, including blood, except for spleen and liver which had about a three times higher uptake of the 99mTc conjugate. In conclusion, 99mTc can be coupled conveniently at high specific activity to 3F8 without compromising immunoreactivity. SHNH appears to be a useful linker for 99mTc in tumor diagnostic imaging and may have potential utility in coupling other radioisotopes (e.g., 94mTc) for positron imaging and therapy. Copyright (C) 1999 Elsevier Science Inc.
99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors